Biopharmaceutical Pipeline
Alzheimer’s Disease
5.7 Million
Americans who suffer with Alzheimer’s Disease
14 Million
Americans who will suffer with Alzheimer’s Disease by 2050
$25 Billion
Total Addressable Market by 2027
Traumatic Brain Injury
$2.7 Billion
Total Addressable Market
PTSD
$7.3 Billion
Total Addressable Market
Anxiety/Depression
$15.6 Billion
Total Addressable Market